Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients

Clin Infect Dis. 2005 Dec 15;41(12):1812-6. doi: 10.1086/498151. Epub 2005 Nov 7.

Abstract

Post-hematopoietic stem cell transplantation (HSCT) adenovirus infections were identified in 31 of 204 consecutive pediatric HSCT patients, 18 of whom had severe manifestations of infection. Cidofovir treatment led to clinical improvement in 8 of 10 patients with severe infection and to virologic clearance in 9 patients. In vitro susceptibility to cidofovir was demonstrated in 12 clinical adenovirus isolates. Cidofovir is a promising treatment option for this population.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / drug effects
  • Adenovirus Infections, Human / drug therapy*
  • Adenovirus Infections, Human / etiology*
  • Adolescent
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Cidofovir
  • Cytosine / analogs & derivatives*
  • Cytosine / pharmacology
  • Cytosine / therapeutic use
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Microbial Sensitivity Tests
  • Organophosphonates / pharmacology
  • Organophosphonates / therapeutic use*

Substances

  • Antiviral Agents
  • Organophosphonates
  • Cytosine
  • Cidofovir